Fiorani P, Speziale F, Rizzo L, Sbarigia E, Massucci M, Rached H A
Département de Chirurgie Vasculaire, Policlinico Umberto, Rome, Italie.
J Mal Vasc. 1996;21 Suppl A:162-6.
Secondary aorto-enteric fistula is one of the most serious complications of abdominal aortic reconstruction. Conventional management includes removal of all infected prosthetic graft, oversewing of aortic stump and restoration of lower limbs blood flow by extraanatomic bypass grafting, reporting high rates of mortality, limb loss, and even infection of the extraanatomic grafts. Dissatisfied by these results, frequently, due to aortic stump blowout or extraanatomic by-pass reinfection, some authors attempted a more conservative approach with au in situ replacement by a new synthetic graft. The aim of this paper was to verify the role of in situ graft replacement. From December 1989, 8 patients with secondary aorto-enteric fistula underwent in situ PTFE graft replacement. One patient (12.5%) died perioperatively for acute myocardial infarction. No limb loss occurred. One patient died after 44 months from pulmonary neoplasia without signs of graft infection. The others are doing well at 34 months follow-up. The authors suggest that, in selected patients, in situ prosthetic graft replacement provides better early and late results than extranatomic bypass.
继发性主动脉肠瘘是腹主动脉重建最严重的并发症之一。传统治疗方法包括切除所有感染的人工血管移植物、缝合主动脉残端以及通过解剖外旁路移植恢复下肢血流,但报道显示其死亡率、肢体缺失率较高,甚至解剖外移植物也会发生感染。由于对这些结果不满意,且常因主动脉残端破裂或解剖外旁路再次感染,一些作者尝试采用更保守的方法,即使用新的人工合成移植物进行原位置换。本文的目的是验证原位移植物置换的作用。自1989年12月起,8例继发性主动脉肠瘘患者接受了原位聚四氟乙烯移植物置换。1例患者(12.5%)围手术期死于急性心肌梗死。未发生肢体缺失。1例患者在44个月后死于肺肿瘤,无移植物感染迹象。其他患者在34个月的随访中情况良好。作者认为,对于选定的患者,原位人工血管移植物置换比解剖外旁路移植能提供更好的早期和晚期效果。